| Paris | |
| 15 | |
| IntegraGen specializes in deciphering the human genome by performing genomic analyses and high-throughput sequencing for clinical and research laboratories while also developing molecular diagnostic tools for oncology. | |
| IntegraGen has developed a molecular signature which molecularly classifies tumors from patients with hepatocelluar carcinoma (HCC) based on the tumor's genetic makeup. This signature also identifies the prognosis and recurrence risk for patients with liver cancer. IntegraGen is developing a predictive test based on the biomarker miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR (epidermal growth factor receptor) monoclonal antibody therapy response in wild-type KRAS patients with metastatic colorectal cancer. IntegraGen is developing a molecular test based on the biomarker hsa-miR-31-3p, a microRNA whose expression has been correlated with the effect of EGFR TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) in patients with advanced non-small cell lung cancer (NSCLC). The ARISk Test is a genetic test designed to identify the risk of autism spectrum disorder (ASD) in children who have signs of developmental delay, a clinical suspicion of autism, or an older sibling previously diagnosed with an ASD. |
|
| RIOT LAMOTTE Laurence | |
| www.integragen.fr |
Fiche créée le 10/04/2016 par 
Guillaume vue 5 fois.